The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro

Surgery Today

Volumn 26, Issue 2, 1996, Pages 83-88

  Hideshima, Teru ^a   Iwasaki, Akinori ^a   Baba, Miki ^a   Yamashita, Yuichi ^a   Shirakusa, Takayuki ^a   Okada, Hidechika ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

bispecific antibody; carcinoma; CEA; cytotoxicity

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB5C10; MONOCLONAL ANTIBODY CD3; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; STOMACH CANCER;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; MICE; MICE, INBRED BALB C; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0029993738     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00311769     Document Type: Article

References (16)

1. Garcia DE, Palazzo I, Gercel-Taylor C, Kitson J, Weiner LM (1990) Potentiation of tumor lysis by a bispecific antibody that hinds to CA19-9 antigen and the Fcr receptor expressed by human large granular lymphocytes. Cancer Res 50:7123-7128
2. Bohlen H, Manzke B, Moldenhauler G, Dorken B, Fliedner V, Tesch H (1993) Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 53:4310-4314
3. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake P, Diehl V, Tesch H (1993) Lysis of malignant B cell from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3XCD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803-1812
4. Duke-Cohan J, Morimoto C, Schlossman S (1993) Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26, Blood 82:2224-2234
5. Berhnard H, Karbach J, Strittmatter C, Buschenfelde K-H, Knuth K (1993) Induction of tumor-cell lysis by bi-specific antibody recognition ganglioside GD2 and T-cell antigen CD3. Int J Cancer 55:465-470
6. Mulé J, Shu S, Rosenberg S (1985) the anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 135:646-652
7. Rosenberg S, Spiess P, Lofreniere R (1986) A now approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
8. Rosenberg S, Lotze M, Muul L, Chang A, Fred F, Leitman S, Linehan W, Robertson C, Lea R, Rubin J, Seipp C, Sinepson C, White D (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897
9. Fanger W, Shen L, Graziano R, Guyre M (1989) Cytotoxicity mediated by human Fc receptors for IgO. Immunol Today 10: 92-99
10. Okada H, Momota H, Azuma T, Hattori T, Okada N (1992) Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies. Immunol Lett 31:247-252
11. Okada H, Momota H, Okada N, Okamoto T, Azuma T (1993) Elimination of HIV-infected cells by lymphocytes armed with a bifunctional antibody to gp120 of HIV and CD3. Immunol Lett 38:195-199
12. Ramsey SP, Dean AP, Tasimowicz-Alpini A, Donohue HJ, Nelson M (1993) Interferon-r-induced intercellular adhesion molecule-1: Expression of human tumor cells enhances bifunctional antibody-mediated lysis through a lymphocyte function-associated antigen-1 dependent mechanism. Cancer Res 53: 4652-4657
13. Hombach A, Jung W, Pohl C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M (1993) A CD16/CD30 bispecific monoclonal antibody induced lysis of Hodgkin's cell by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830-836
14. Ferrini S, Cambiaggi A, Sforzini S, Marciano S, Canevari S, Mezzanzanica D, Colanaghi M, Grossi C, Moretta L (1993) Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for T-cell activation. Int J Cancer 55: 931-937
15. Kroesen B, Haar A, Spakman H, Willemse P, Sleijfer D, Vries E, Mukder N, Berendsen H, Limburg P, The T, Leij L (1993) Local antitumour treatment in carcinoma patients w ith bispecific-monoclonal-antibody-restricted T cells Cancer Immunol Immunother 37:400-407
16. Blank-Voorthuis C, Braakman E, Ronteltap C, Tilly B, Sturm E, Warnaar S, Bolhuis R (1993) Clustered CD3/TCR complex does not transduce activation signals after bispecific monoclonal antihody-triggred lysis by cytotoxic T lymphocytes via CD3. J Immunol 151:2904-2914